01—Abstract
Summary
Summary of the 10-K filed February 19, 2014. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2013 10-K filing reveals a company navigating patent expirations while investing heavily in research and development for future growth.
The company reported a 2% increase in worldwide revenue to $23.11 billiona, driven by strong performance in key products like Cialis, Humalog, and Trajenta, alongside its animal health division. Net income saw a significant 15% increase to $4.68 billion, largely due to improved gross margins and lower operating expenses, further boosted by a lower effective tax rate and share repurchases. However, the report also highlights significant challenges.
Cymbalta lost U.S. patent exclusivity in December 2013, leading to immediate generic competition and expected rapid revenue declines. Evista is also set to face similar pressures with patent expiration in March 2014.
The company is actively managing these patent cliffs through robust R&D pipelines, with several promising candidates in late-stage development across therapeutic areas like diabetes, oncology, and neuroscience. Despite these challenges, Lilly's financial health appears solid, supported by strong cash flow and a commitment to returning value to shareholders through dividends and share repurchases.
02—Key points
Key Highlights
- Worldwide revenue grew 2% to $23.11 billion in 2013, with net income up 15% to $4.68 billion.
- Key product growth drivers included Cialis, Humalog, Trajenta, Alimta, and Forteo, along with the Elanco animal health division.
- Significant revenue erosion is expected for Cymbalta and Evista due to recent and upcoming patent expirations.
- Research and development expenses increased 5% to $5.53 billion, reflecting continued investment in new drug development.
- The company actively repurchased shares, repurchasing $1.70 billion in 2013.
- Lilly is managing its legal and regulatory environment, including ongoing patent litigation for Alimta and investigations into marketing practices.
- The company has a strong late-stage pipeline with multiple promising new molecular entities across various therapeutic areas.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2013filed February 19, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $23.11B$22.60B | +2.3% |
| Cost of Revenue | $4.91B$4.80B | +2.3% |
| Gross Profit | $18.20B$17.81B | +2.2% |
| R&D Expenses | $5.53B$5.28B | +4.8% |
| SG&A Expenses | $7.13B$7.51B | −5.2% |
| Interest Expense | $160.10M$177.80M | −10.0% |
| Net Income | $4.68B$4.09B | +14.6% |
| EPS (Basic) | $4.33$3.67 | +18.0% |
| EPS (Diluted) | $4.32$3.66 | +18.0% |
| Shares Outstanding (Basic) | 1.08B1.11B | −2.9% |
| Shares Outstanding (Diluted) | 1.08B1.12B | −2.9% |
05—Questions
Frequently Asked Questions
What are the main products driving Eli Lilly's revenue in 2013?
In 2013, Eli Lilly's revenue growth was driven by products such as Cialis, Humalog, Trajenta, Alimta, and Forteo. The Elanco animal health division also contributed positively to the company's top-line performance.
What are the major risks or challenges facing Eli Lilly based on this filing?
The primary challenges highlighted are the loss of patent exclusivity for key products like Cymbalta and Evista, which is expected to lead to significant revenue declines due to generic competition. The company also faces intense competition, the high cost and uncertainty of pharmaceutical R&D, and increasing government price controls and regulations globally.
How is Eli Lilly addressing the impact of patent expirations?
Eli Lilly is addressing patent expirations by heavily investing in its research and development pipeline. The company has numerous drug candidates in various stages of development, including several in late-stage clinical trials for diseases such as diabetes, cancer, and Alzheimer's. This R&D focus is crucial for replacing revenue lost from products going off-patent.
What is the company's financial health and outlook based on this report?
The company demonstrates a strong financial position with a 15% increase in net income and a healthy gross margin. Despite the anticipated revenue impact from patent expirations, Lilly's financial outlook for 2014 projected revenues between $19.2 billion and $19.8 billion, indicating resilience. The company is also committed to shareholder returns through dividends and share repurchases, supported by operating cash flow.
06—Continue